Long-term treatment with XXXX : monitoring of venous @entity3265 concentrations and adverse effects.

@entity1 @entity3265 @entity1092 @entity344 @entity2052 @entity109 @entity302 @entity3174 @entity400 @entity1017 @entity2049
Adverse effects and venous blood @entity3265 concentrations were monitored over a period of 7 months in @entity1 with @entity302 treated with @entity1092 ( @entity2052 ). During the 1st, 4th, 12th, 20th, and 28th weeks of therapy, blood samples for analysis of @entity3265 and anticonvulsants were taken immediately before the morning dose of @entity2052 as well as 2 h after dosing. In all, 40 @entity1 completed the follow-up; 16 of these (Group 1) received @entity2052 alone, while the remaining 24 (Group 2) were treated simultaneously with @entity2052 and other anticonvulsants ( @entity109 , @entity3174 , and/or @entity2049 ). In Group 1 @entity1 , a slight though significant increase in @entity3265 concentrations was found during long-term @entity2052 treatment; this trend was even more pronounced in Group 2 @entity1 . The difference between postdose and predose @entity3265 levels in Group 2 @entity1 was significant at each of the five follow-up examinations. In contrast, no such difference was demonstrated in @entity1 of Group 1. @entity2052 concentrations were found to be consistently higher in Group 2 @entity1 than in Group 1. Twenty-three @entity1 complained of various long-term adverse effects, while the other 17 remained symptom-free. The adverse effects reported included drowsiness, @entity400 , @entity1017 , hair loss, and @entity344 . Our data confirm the previously suggested hypothesis that changes in venous blood @entity3265 are particularly evident in @entity1 taking @entity2052 in combination with other antiepileptic drugs, such as @entity109 and @entity3174 .
